<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542971</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0977</org_study_id>
    <nct_id>NCT00542971</nct_id>
  </id_info>
  <brief_title>Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)</brief_title>
  <official_title>Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral VEGF, RAF and FLT3 Inhibitor, in Patients With High-risk MDS and AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A primary goal of this clinical research study is to find the highest safe dose of sorafenib
      that can be given in combination with idarubicin and Ara-C for the treatment of acute
      myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS).

      Once the highest safe dose is found, researchers will then try to learn if this combination
      treatment can help control AML and high-risk MDS in newly diagnosed patients. The safety of
      this treatment combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Sorafenib is designed to block the function of important proteins in cancer cells. When
      active, these proteins help cause abnormal growth and behavior of leukemia cells.

      Idarubicin and Ara-C are both designed to insert themselves into DNA (the genetic material of
      cells) and to stop DNA from repairing itself.

      Study Groups:

      If you are found to be eligible to take part in this study, you will be assigned to a study
      group based on when you join this study.

      If you are enrolled in the Phase I part of this study, the dose of sorafenib you receive with
      Ara-C and idarubicin will depend on when you enrolled in this study. Each new group of 3
      participants will receive a higher dose level of sorafenib than the previous group until the
      highest safe dose of sorafenib that can be given in combination with Ara-C and idarubicin is
      reached.

      If you are enrolled in the Phase II portion of this study, you will receive the highest safe
      dose of sorafenib in combination with Ara-C and idarubicin found in the Phase I part.

      Study Drug Administration:

      During the study, you will receive treatment over 28-day &quot;cycles.&quot; The doses of idarubicin
      and Ara-C are the same for all study participants.

      On Days 1-4 (Days 1-3 if you are older than 60) of each induction cycle (#1 and possibly #2),
      you will receive Ara-C through a nonstop infusion (through a needle in your vein). You will
      also receive steroids by mouth or through a vein every day to reduce the risks of side
      effects, such as rash.

      On Days 1-3 of each induction cycle (#1 and possibly #2), you will receive idarubicin by vein
      over 1 hour once a day.

      In general, sorafenib will be taken by mouth twice daily on Days 1-7, unless otherwise
      instructed. However, the dose of sorafenib may differ among study participants. Sorafenib
      should be taken with water on an empty stomach. Your study doctor will give you complete
      instructions on when and how to take sorafenib.

      Depending on the side effects that you may have, the dose of sorafenib may be decreased,
      stopped until side effects go away, or even stopped completely, if your doctor thinks that
      this is in your best interest.

      Study Visits:

      During Cycles 1-2, you will have study visits about 2 times a week. You may need to have
      study visits more often when the study doctor thinks it is necessary. At these visits, you
      will have the following procedures performed.

        -  You will be asked about any side effects you may have experienced and any medications
           you may be taking.

        -  Blood (about 2 teaspoons) will be drawn for routine tests.

      During Cycles 1 and 2, between Days 21-28, you will have a bone marrow aspirate and/or biopsy
      performed to check the status of the disease.

      For Cycle 3 and in further cycles, you will have a bone marrow aspirate as determined
      necessary by your doctor. If your doctor thinks you have responded to the treatment, you will
      then have bone marrow aspirates collected every 3-6 months, if your doctor feels this to be
      necessary.

      Consolidation Therapy:

      If it is found that the disease is responding to treatment, you may receive 5 additional
      cycles of therapy. These cycles are called &quot;consolidation&quot; therapy and will be given every
      4-6 weeks.

      On Days 1-3, Ara-C will be given as a nonstop infusion. You will also receive steroids either
      by mouth or by vein to help reduce the risk of side effects.

      On Days 1-2, idarubicin will be given by vein over 1 hour.

      Sorafenib will be taken twice daily by mouth for 7 or more days, at a schedule determined by
      your study doctor.

      After each cycle, about every 4-6 weeks, blood (about 2 teaspoons) will be drawn to check
      your blood count levels.

      Maintenance Therapy:

      After 5 cycles of consolidation therapy, and according to your response to consolidation
      therapy, you may continue on this study to receive &quot;maintenance&quot; treatment, as needed, and as
      determined by your study doctor for up to 7 more cycles.

      You will take sorafenib twice a day every day during the 28-day cycle.

      Every 1-4 weeks, blood (about 2 teaspoons) will be drawn for routine tests.

      Length of Study:

      You may receive up to 14 cycles in total of therapy. You may be taken off this study if the
      leukemia gets worse, develop another illness that interferes with taking the study drugs, or
      you have intolerable side effects.

      This is an investigational study. Sorafenib is FDA approved and commercially available for
      the treatment of metastatic renal cancer only. Idarubicin is FDA approved for use in
      combination with other approved antileukemic drugs for the treatment of acute myeloid
      leukemia (AML) in adults. Cytarabine is FDA approved for use in the treatment of leukemia.
      The use of sorafenib combined with idarubicin and Ara-C in the treatment of AML and high-risk
      MDS is investigational and authorized for use in research only. Up to 75 patients will take
      part in this study. All patients will be enrolled at M. D. Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Twice a week for first two 28 day cycles</time_frame>
    <description>MTD is dose level where grade 3-4 sorafenib-attributable toxicity in &lt;2 of 6 participants. Dose-Limiting Toxicity graded according to the NCI Common Toxicity Criteria version 3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>Baseline to 2 years or disease progression.</time_frame>
    <description>Complete response was defined by the presence of &lt; 5% blasts in the bone marrow (BM) with &gt; 1 x 10^9/L platelets in the peripheral blood (PB).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>AML</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Disorders</condition>
  <arm_group>
    <arm_group_label>Sorafenib + Idarubicin + Ara-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m2 IV over 1 hour daily (days 1-3)</description>
    <arm_group_label>Sorafenib + Idarubicin + Ara-C</arm_group_label>
    <other_name>Idamycin®, Idamycin PFS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Starting dose 400 mg by mouth for 7 days</description>
    <arm_group_label>Sorafenib + Idarubicin + Ara-C</arm_group_label>
    <other_name>Nexavar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
    <arm_group_label>Sorafenib + Idarubicin + Ara-C</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar-U®</other_name>
    <other_name>Arabinosylcytosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of 1) AML (World Health Organization classification definition of &gt; 20%
             blasts), or 2) high risk MDS (defined as the presence of &gt; 10% blasts).

          2. Patients aged 15 to 60 years are eligible. Patients older than 60 who are deemed fit
             to receive intensive chemotherapy by the treating physician are eligible after
             discussion with the Principal Investigator (PI). For the Phase II portion of the
             study, patients must be chemo-naïve, i.e. not have received any prior chemotherapy
             (except hydrea) for AML or MDS. They could have received hypomethylator agents,
             transfusions, hematopoietic growth factors or vitamins. Temporary prior measures such
             as pheresis or hydrea are allowed. In the Phase I portion, patients with relapsed or
             refractory AML/MDS are also eligible.

          3. Serum biochemical values with the following limits unless considered due to leukemia:
             1) creatinine less than or equal to 2 mg/dl, 2) total bilirubin less than or equal to
             2 mg/dL, unless increase is due to hemolysis or congenital disorder, and 3)
             transaminases (SG PT) less than or equal to 2.5 times ULN

          4. Ability to take oral medication.

          5. Ability to understand and provide signed informed consent.

          6. Baseline test of ejection fraction must be &gt;/=50%.

          7. Performance status &lt; 3, unless directly related to the disease process as determined
             by the principal investigator.

        Exclusion Criteria:

          1. Patients with Acute promyelocytic leukemia (APL).

          2. Any coexisting medical condition that in the judgment of the treating physician is
             likely to interfere with study procedures or results.

          3. Nursing women, women of childbearing potential with positive urine pregnancy test, or
             women of childbearing potential who are not willing to maintain adequate contraception
             (such as birth control pills, IUD, diaphragm, abstinence, or condoms by their partner)
             over the entire course of the study.

          4. Any significant, uncontrolled hypertension.

          5. Cardiac disease: Congestive heart failure &gt; class II The New York Heart Association
             (NYHA). Patients must not have unstable angina (anginal symptoms at rest) or new onset
             angina (began within the last 3 months) or myocardial infarction within the past 6
             months.

          6. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Sorafenib is
             contraindicated in patients with known severe hypersensitivity to sorafenib or any of
             the excipients.

          7. Known human immunodeficiency virus (HIV) infection or active Hepatitis B or C.

          8. Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months.

          9. Pulmonary hemorrhage/bleeding event &gt; or = to Common Terminology Criteria for Adverse
             Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug.

         10. Any other hemorrhage/bleeding event &gt; or = to CTCAE Grade 3 within 4 weeks of first
             dose of study drug.

         11. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug.

         12. Use of St. John's Wort or rifampin.

         13. Known or suspected allergy to sorafenib or any agent given in the course of this
             trial.

         14. Active clinically serious and uncontrolled infection &gt; CTCAE Grade 2

         15. Serious non-healing wound, ulcer, or bone fracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi-Kashani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's website</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>June 12, 2012</results_first_submitted>
  <results_first_submitted_qc>June 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2012</results_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>High-Risk MDS</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>High-Risk Myelodysplastic Disorder</keyword>
  <keyword>Idarubicin</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>BAY43-9006</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2007 to February 2009. All participants were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 78 participants registered on this study, three (3) were excluded prior to receiving treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib + Idarubicin + Ara-C</title>
          <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib + Idarubicin + Ara-C</title>
          <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>MTD is dose level where grade 3-4 sorafenib-attributable toxicity in &lt;2 of 6 participants. Dose-Limiting Toxicity graded according to the NCI Common Toxicity Criteria version 3.0.</description>
        <time_frame>Twice a week for first two 28 day cycles</time_frame>
        <population>10 participants were treated with escalating doses of sorafenib with chemotherapy to establish the feasibility of the combination.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Idarubicin + Ara-C</title>
            <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>MTD is dose level where grade 3-4 sorafenib-attributable toxicity in &lt;2 of 6 participants. Dose-Limiting Toxicity graded according to the NCI Common Toxicity Criteria version 3.0.</description>
          <population>10 participants were treated with escalating doses of sorafenib with chemotherapy to establish the feasibility of the combination.</population>
          <units>milligrams/twice a day (BID)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response</title>
        <description>Complete response was defined by the presence of &lt; 5% blasts in the bone marrow (BM) with &gt; 1 x 10^9/L platelets in the peripheral blood (PB).</description>
        <time_frame>Baseline to 2 years or disease progression.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Idarubicin + Ara-C</title>
            <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>Complete response was defined by the presence of &lt; 5% blasts in the bone marrow (BM) with &gt; 1 x 10^9/L platelets in the peripheral blood (PB).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 4 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib + Idarubicin + Ara-C</title>
          <description>Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m2 IV over 24 hours daily (days 1-4)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>All events were unrelated to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage Bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia/Infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="27" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash Hand Foot Reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash Desquamation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farhad Ravandi-Kashani, M.D./Associate Professor</name_or_title>
      <organization>The University of MD Anderson Cancer Center</organization>
      <phone>713-745-0394</phone>
      <email>fravandi@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

